AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16421658
Drug: Self-administered format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered format (SA)
Trial: 15474212
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug names
Trial: 9247610
Drug: Carboplatin administered
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered on a single-day schedule
Trial: 9247610
Drug: Carboplatin administered
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered on a 5-day schedule
Trial: 9247610
Drug: Calvert's formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calvert's formula for dosing carboplatin
Trial: 8320627
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 5 mg/kg per day for 6 months
Trial: 21081776
Drug: Aprepitant 40
RxNorm normalized name: aprepitant 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 40 mg with dexamethasone 10 mg
Trial: 21081776
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV with dexamethasone 10 mg
Trial: 15525294
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg/day for 24 months (total exposure up to 36 months)
Trial: 10086898
Drug: L-thyroxine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine supplementation (placebo group)
Trial: 7843446
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (hyperprolactinemia) with PRL > 20 ng/mL
Trial: 7843446
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (control) with PRL ≤ 20 ng/mL
Trial: 836010
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Trial: 836010
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Trial: 836010
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Trial: 836010
Drug: Intramuscular and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular and oral administration of amoxicillin
Trial: 836010
Drug: Total absorption
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total absorption of amoxicillin (via urinary recovery and AUC)
Trial: 23703915
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with strengthening exercises
Trial: 19411662
Drug: tolvaptan (vasopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolvaptan (vasopressin antagonist)
Trial: 17716313
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD; 20 mg bid)
Trial: 15222726
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (10 mg generic amlodipine)
Trial: 15222726
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (10 mg amlodipine)
Trial: 17545892
Drug: Liquid carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid carbohydrate (CHO) (200 mL.h, 20% CHO (40 g.h, 160 kcal.h))
Trial: 17545892
Drug: Liquid CHO
RxNorm normalized name: BOOST LIQUID CHOCOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid CHO (200 mL.h, 20% CHO (40 g.h, 160 kcal.h)) every even hour and solid CHO (25 g of CHO, 10 g of protein, 2 g of fat, and 160 kcal.h) every odd hour
Trial: 11488319
Drug: Repeated low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Repeated low-dose allergen exposure
Trial: 9791040
Drug: Neutral endopeptidase
RxNorm normalized name: Neutral endopeptidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral endopeptidase inhibitor (SCH 32615, 200 mg intravenously)
Trial: 29949479
Drug: 40-minute application
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-minute application of 38% hydrogen peroxide bleaching agent
Trial: 29949479
Drug: Two 20-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 20-minute applications of 38% hydrogen peroxide bleaching agent
Trial: 24439637
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency TENS treatment
Trial: 19712802
Drug: Testosterone (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (intramuscular injection every 6 weeks)
Trial: 15223252
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (i.v.IG)
Trial: 11259862
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg for two days)
Trial: 9482562
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terfenadine and pseudoephedrine
Trial: 8046193
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (physician-targeted treatment recommendations)
Trial: 3242386
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg x 3)
Trial: 3242386
Drug: Estramustine (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estramustine (280 mg x 2)
Trial: 27918744
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg + Esomeprazole 20 mg (NE)
Trial: 26353772
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with S-1/irinotecan/bevacizumab (SIRB or IRIS/bevacizumab)
Trial: 21219394
Drug: Water-cooled Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-cooled Nd:YAG laser (1064 nm, 6 W, 400 mJ) adjunctive to supra- and subgingival debridement (SRP)
Trial: 9063317
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G (single-dose)
Trial: 8224684
Drug: Rectal endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal endoscopic ultrasonography
Trial: 23998557
Drug: Propionyl-L-carnitine (PLC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PLC) 2g/day orally for 4 months
Trial: 17692951
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ACEI or angiotensin receptor blocker)
Trial: 9196934
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide hydrochloride (3 times a day and 5 times a day)
Trial: 9196934
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide (2 weeks)
Trial: 8466377
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss intervention (18 months duration, 14 weekly group meetings followed by monthly maintenance sessions)
Trial: 3803130
Drug: Graded esophageal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded esophageal balloon distention (10 cc total volume, inflated with 1-cc increments)
Trial: 3803130
Drug: Intraesophageal acid
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAESOPHAGEAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraesophageal acid perfusion and intravenous edrophonium (80 micrograms/kg)
Trial: 29436329
Drug: internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive-behavioural therapy (iCBT) with protocol-driven therapist feedback
Trial: 29436329
Drug: internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive-behavioural therapy (iCBT) with feedback on demand
Trial: 20533013
Drug: Closed-loop system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop system for propofol administration
Trial: 20533013
Drug: Manual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual administration of propofol (Control)
Trial: 18606952
Drug: Acid-suppressing agents
RxNorm normalized name: BULKING AGENT,APPETITE SUPPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-suppressing agents
Trial: 11549099
Drug: Cilomilast (Ariflo)
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast (Ariflo) 15 mg, single and repeat doses, taken before or between meals
Trial: 11549099
Drug: Cilomilast (Ariflo)
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast (Ariflo) 30 mg, repeat doses, taken after meals
Trial: 7908358
Drug: Very-low-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose warfarin (1 mg daily for 6 weeks, adjusted to maintain INR of 1.3 to 1.9)
Trial: 7908358
Drug: Very-low-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose warfarin and Placebo
Trial: 363751
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate (P) 50 mg
Trial: 363751
Drug: Fenoprofen calcium
RxNorm normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenoprofen calcium (F) 600 mg
Trial: 363751
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of P and F (P50 + F50)
Trial: 363751
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of P and F (P200 + F50)
Trial: 363751
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of P and F (P200 + F200)
Trial: 363751
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of P and F (P200 + F600)
Trial: 26209747
Drug: Weekly ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly ergocalciferol (50,000 IU) supplementation
Trial: 24102055
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (3 cups daily for 14 weeks)
Trial: 15508793
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AA)
Trial: 9272339
Drug: DTPwc vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPwc vaccine
Trial: 3235234
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol (for men)
Trial: 26269563
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication and treatment with antioxidants
Trial: 22762359
Drug: Two small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two small diameter implants (SDI) ‐ retained overdenture (study group)
Trial: 18463993
Drug: Dextromethorphan and
RxNorm normalized name: Dextromethorphan and menthol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan and quinidine (DM/Q) 30 mg/30 mg, twice a day
Trial: 17063976
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion (CIVS) of lorazepam
Trial: 17063976
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of lorazepam
Trial: 17063976
Drug: CIVS administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIVS administration
Trial: 9863096
Drug: Fufang Qingdai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Qingdai Capsule (FQC)
Trial: 31023352
Drug: Adolescent Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent Cognitive Therapy for Anxiety (ACTA) - six 60-90 min sessions and a booster session
Trial: 31023352
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behaviour Therapy (CBT) - eight 2-h sessions and a booster session
Trial: 21970061
Drug: Standard vocal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vocal therapy (Group I, n=33)
Trial: 21970061
Drug: Larynx compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Larynx compression vocal therapy (Group II, n=33)
Trial: 15536840
Drug: Bionator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionator therapy (n = 14)
Trial: 9301391
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution 25 ml kg‐1 over 30 min (in males)
Trial: 9301391
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution 25 ml kg‐1 over 30, 45, and 80 min (in females)
Trial: 1376962
Drug: Bunazosin hydrochloride
RxNorm normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin hydrochloride (1.5 mg/day)
Trial: 1376962
Drug: Bunazosin hydrochloride
RxNorm normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin hydrochloride (3.0 mg/day)
Trial: 29754811
Drug: Integrated Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Exposure Therapy and Exercise
Trial: 27020000
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Bipolar radiofrequency potentiated with infrared light and fractional bipolar radiofrequency)
Trial: 25004496
Drug: Psychological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy for 12 weeks
Trial: 21988617
Drug: Isoflavone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone (60 mg/day) for 12 months
Trial: 21988617
Drug: Isoflavone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone (60 mg/day)
Trial: 18030233
Drug: Bravo pH
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bravo pH capsule
Trial: 16118573
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) ingestion (4 mL.kg.15 min of 6%)
Trial: 10428349
Drug: CDE during
RxNorm normalized name: 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
DrugBank: Ellagic acid (DB08846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDE during treatment
Trial: 1681365
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated capsules of Ty21a vaccine
Trial: 1681365
Drug: Placebo (liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (liquid formulation)
Trial: 6345649
Drug: Mepenzolate bromide
RxNorm normalized name: Mepenzolate Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepenzolate bromide (MZB) 50 mg, taken 4 times daily for 48 hours
Trial: 6345649
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken 4 times daily for 48 hours
Trial: 31575091
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 µg) and Coenzyme Q10 (200 mg) daily for four years
Trial: 24622750
Drug: Indirect infant
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect infant supplementation (400 mg iodine to the mother, placebo to the infant)
Trial: 24622750
Drug: Direct infant
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct infant supplementation (100 mg iodine to the infant, placebo to the mother)
Trial: 20218995
Drug: 5 IU
RxNorm normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU oxytocin bolus and 30 IU infusion
Trial: 10357338
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of alkalinized lidocaine with 0 microg phenylephrine (Group 1)
Trial: 10357338
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of alkalinized lidocaine with 50 microg phenylephrine (Group 2)
Trial: 10357338
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of alkalinized lidocaine with 100 microg phenylephrine (Group 3)
Trial: 10357338
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of alkalinized lidocaine with 200 microg phenylephrine (Group 4)
Trial: 1672870
Drug: Cyclophosphamide/ACTH treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide/ACTH treatment
Trial: 29172994
Drug: Amiloride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (10 mg daily for 5 months)
Trial: 23998168
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medications (PIMs) prescribed, including amitriptyline, dextropropoxyphene, quinine, and benzodiazepines.
Trial: 23998168
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of inappropriate medication use between those with and without significant depressive symptoms
Trial: 21283922
Drug: Fluocinonide 0.1%
RxNorm normalized name: FLUOCINONIDE 0.1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide 0.1% cream applied once daily for two weeks
Trial: 21283922
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied once daily for two weeks (control)
Trial: 17549479
Drug: Gemcitabine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine at standard rate (1,200 mg/m2 over 30 min) + Carboplatin (AUC of 5 over 4 h)
Trial: 17549479
Drug: Gemcitabine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine at fixed dose rate (1,200 mg/m2 over 120 min) + Carboplatin (AUC of 5 over 4 h)
Trial: 11684971
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia combined with light general anesthesia and postoperative intravenous patient-controlled analgesia
Trial: 11684971
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia alone with postoperative intravenous patient-controlled analgesia
Trial: 9831221
Drug: Mepartricin 40
RxNorm normalized name: mepartricin
DrugBank: Mepartricin (DB13633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin 40 mg/daily
Trial: 31247504
Drug: Non-opioid agonist
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid agonist treatment (non-OAT)
Trial: 25431430
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (primarily individual-based CBT)
Trial: 19299776
Drug: Pregabalin 75-300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75-300 mg
Trial: 17708607
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) therapy for 6 weeks